Evidence map›Paper›PMID 37910805›Full record

Observational studyJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Evaluation of the Impact of Meibomian Gland Dysfunction Using a Novel Patient-Reported Outcome Instrument.

Layla Ajouz, Joelle Hallak, Rupali Naik, Ashley Nguyen, Cathy Zhao, Michael R Robinson, Kelly K Nichols

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Changes in Human Meibum Lipid Composition Related to the Presence and Severity of Meibomian Gland Dysfunction.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Layla AjouzAllergan (an AbbVie company), Irvine, California, USA.
Joelle HallakAllergan (an AbbVie company), Irvine, California, USA.
Rupali NaikNoesis Healthcare Technologies, Redwood City, California, USA.
Ashley NguyenAllergan (an AbbVie company), Irvine, California, USA.
Cathy ZhaoAllergan (an AbbVie company), Irvine, California, USA.
Michael R RobinsonAllergan (an AbbVie company), Irvine, California, USA.
Kelly K NicholsSchool of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Allergan (Ireland) · IEGenesis HealthCare · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dry Eye SyndromesMeibomian Gland DysfunctionAdultHumansMeibomian GlandsProspective StudiesQuality of LifeTearsmeibomian gland dysfunctionMeibomian Gland Dysfunction Impact Questionnairepatient-reported outcome measuresquality of life

Identifiers

PMID37910805
PMCPMC10890943
OpenAlexW4388124772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.